Lazard Asset Management
PBYI icon

Lazard Asset Management’s Puma Biotechnology PBYI Stock Holding History

Lazard Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,970
Closed -$115K – 2084
2026
Q1 		$115K Sell
17,970
-41,605
-70% -$268K ﹤0.01% 1711
2025
Q4 		$354K Sell
59,575
-3,572
-6% -$19K ﹤0.01% 1480
2025
Q3 		$335K Buy
+63,147
New +$268K ﹤0.01% 1469
2025
Q2 		– Sell
-2,100
Closed -$6K – 2474
2025
Q1 		$6K Sell
2,100
-395
-16% -$1.24K ﹤0.01% 2176
2024
Q4 		$7K Buy
2,495
+2,005
+409% +$5.83K ﹤0.01% 2118
2024
Q3 		$1K Sell
490
-107,413
-100% -$325K ﹤0.01% 2189
2024
Q2 		$351K Buy
107,903
+58,437
+118% +$257K ﹤0.01% 1347
2024
Q1 		$262K Buy
49,466
+48,520
+5,129% +$261K ﹤0.01% 1217
2023
Q4 		$4K Buy
+946
New +$3.13K ﹤0.01% 2132
2021
Q3 		– Sell
-6,984
Closed -$64K – 2254
2021
Q2 		$64K Buy
+6,984
New +$70.8K ﹤0.01% 1501

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's PBYI Position: Q2 2026 in Review

Lazard Asset Management sold out of Puma Biotechnology (PBYI) in Q2 2026, closing a stake of 17,970 shares — an estimated $115K sold.

Lazard Asset Management first reported a position in PBYI in Q2 2021 and held it in 10 quarters. The position peaked at $354K in Q4 2025. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Lazard Asset Management reported no remaining Puma Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Lazard Asset Management sold 17,970 Puma Biotechnology shares in Q2 2026, an estimated $115K.
  • Lazard Asset Management first reported a position in Puma Biotechnology in Q2 2021 and held it in 10 quarters.
  • Lazard Asset Management's Puma Biotechnology position peaked at $354K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.